Foghorn Therapeutics Inc

NASDAQ FHTX
$5.77 0.38 7.05%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 26.25 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
229.40M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
177.49M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
62.85M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
22.25 %

Upcoming events Foghorn Therapeutics Inc

All events
No upcoming events scheduled

Stock chart Foghorn Therapeutics Inc

Stock analysis Foghorn Therapeutics Inc

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-2.85 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
-5.69 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-2.72 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.80 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
130.47 -50.00

Price change Foghorn Therapeutics Inc per year

3.15$ 9.99$
Min Max

Summary analysis Foghorn Therapeutics Inc

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Foghorn Therapeutics Inc

Revenue and net income Foghorn Therapeutics Inc

All parameters

About company Foghorn Therapeutics Inc

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Address:
500 Technology Square, Cambridge, MA, United States, 02139
Company name: Foghorn Therapeutics Inc
Issuer ticker: FHTX
ISIN: US3441741077
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2020-10-23
Sector: Healthcare
Industry: Biotechnology
Site: https://foghorntx.com